Adding agents that target Ang-Tie2 signaling between ECs and macrophages such as Tie2-neutralizing antibodies, siRNA-targeting Tie2, and inducible Tie2 knockdown in the hematopoietic stem cells in addition to anti-angiogenic agents has yielded promising pre-clinical results, blocking tumor angiogenesis, growth, and metastasis [54]. The gene discussed is ANG; the disease is neoplasm.